Javelin Pharmaceuticals, Inc.
Biotech Specialty Pharma
1979 Marcus Avenue, Suite C102
Lake Success, NY 11042 USA
phone: 212.554.4550
fax: 212.554.4554
Symbol JAV
Exchange AMEX
Founded 0
Employees
javelinpharmaceuticals.com
Research Sector Biotech Specialty Pharma
Summary Description
Product candidates address the acute moderate-to-severe pain medication market.
Management
Daniel B. Carr, MD, Chief Executive Officer & Chief Medical Officer; Fred H. Mermelstein, PhD, President; Stephen J. Tulipano, CPA, MBA, Chief Financial Officer; David B. Bernstein, Esq., General Counsel & Chief Intellectual Property Counsel; Curtis Wright IV, MD, MPH, Vice President, Risk Management & Regulatory Affairs; Michael Moshman, MBA, B.Sc., Vice President, Clinical & Commercial Manufacturing; Michael T. Sheckler, MBA, Vice President, Business Development; Mark Matthews, Vice President, Commercial Affairs; Douglas G. Watson, Chairman; Fred H. Mermelstein, Ph.D., Director; Jackie M. Clegg, Director; Daniel B. Carr, MD, Director; Neil Flanzraich, Director; Martin Driscoll, Director; Georg Nebgen, Ph.D., Director
Ownership
Financials


* numbers in thousands

 
Keywords
post-operative pain, orthopedic injury pain, procedural pain, burn pain and trauma, j2008

Comment | Printable Version | Dec. 04, 2007
If you work for Javelin Pharmaceuticals, Inc. and want to update this profile, click here

Description
Javelin applies proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and under served medical need in the pain management market.
Products / Services
Javelin is currently researching three products for worldwide release: Dyloject, and injectable diclofenac; Rylomine, an intranasal morphine; and PMI-150, an intranasal ketamine.
Technology / Differentiation
Product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments. Javelin's product candidates address the acute moderate-to-severe pain medication market segment. They are developing differentiated pain control products that provide the flexibility and versatility required to address the limitations of existing prescription pain medications in supervised health care settings. Indications under development include post-operative pain, orthopedic injury pain, procedural pain, burn pain and trauma. Currently available formulations of the popular drug diclofenac are insoluble in water. Javelin has successfully improved the solubility of diclofenac by the addition of hydroxypropyl-beta-cyclodextrin (HP-CD) allowing for the creation of a proprietary injectable formulation that can efficiently deliver the drug to the patient's bloodstream.
Market / Customers
Javelin is in the pain management market. They apply innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical needs.
Funding
Javelin is a publicly traded company, traded on the American Stock Exchange.
Status
All products have reached Phase III testing in the United States, and all but Rylomine has reached Phase III in Europe. (Rylomine is currently in Phase II testing).


2008-11-22-220